Navigation Links
Substitution of Pixantrone for Doxorubicin in CHOP Chemotherapy Regimen Produces High Rates of Complete Remissions and Long-Term Disease Free Survival in Patients with Relapsed/Refractory Aggressive NHL Who Previously Failed Frontline CHOP Therapy
Date:4/3/2011

SEATTLE, April 4, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that the April 2011 edition of the peer reviewed journal, Leukemia & Lymphoma (April 2011; 52(4): 620–628) published results of a phase I/II clinical trial evaluating the effect of cyclophosphamide, pixantrone, vincristine, and prednisone ("CPOP") in treating patients with aggressive non-Hodgkin's lymphoma ("NHL") who relapsed following initial therapy with cyclophosphamide, doxorubicin, vincristine (Oncovin), and prednisone ("CHOP").  In the CPOP regimen, pixantrone substitutes for doxorubicin (H) in the CHOP regimen.  Peter Borchmann, M.D., of the University Hospital of Cologne, led the study.  CPOP produced high rates of complete remissions ("CR") and overall response rate ("ORR").  In some patients, these remissions were highly durable despite patients having relapsed after receiving CHOP and other multi-agent therapies.  

The study enrolled 35 patients in the phase I portion of the trial and 30 patients in the phase II portion of the trial. A major tumor response was reported for 80% and 73% of patients in phase I and II respectively, with 57% and 47% of the patients achieving a complete or unconfirmed CR. Median overall survival in the phase II portion of the trial was 17.9 months with four patients achieving notable long-term disease-free survival ranging from 55 to 77 months, despite in some cases having failed multiple prior regimens including stem cell transplantation. High response rates were also observed in the 43% of patients who had received prior rituximab as part of their front-line regimen (CHOP-R), with an ORR rate of 77% and CR rate of 54%. Myelosuppression was the most common toxicity. Side effects (grade 3/4) in phase I of the trial included febrile neutropenia (11%), grade 3/4 infections (3%), and cardiac failure (6%). In phase II of the trial, side effects (grade 3/4) included febril
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDAs Office of New Drugs Meets With Cell Therapeutics on its Appeal on Pixantrone
2. Cell Therapeutics Files Appeal on FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma
3. European Medicines Agency Grants Cell Therapeutics Orphan Drug Designation for Pixantrone in Diffuse Large B-Cell Lymphoma (DLBCL)
4. Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 10, 2010
5. Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines
6. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
7. FDA Sets Action Date of April 23, 2010 for Review of Pixantrone NDA
8. Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
9. Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options
10. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
11. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... /PRNewswire-iReach/ -- Academy Leadership, an elite leadership training firm ... a case study highlighting one manager,s experience ... In September and October 2014, Academy Leadership affiliates are ... , Indianapolis , Salt Lake City , ... http://photos.prnewswire.com/prnh/20140828/140814 Leadership training for managers ...
(Date:8/28/2014)... , Aug. 28, 2014 Nonin Medical, ... leader in noninvasive medical monitoring, today announced that the ... Model 3231 OEM/eHealth finger pulse oximeter for use in ... pulse oximeter plugs into a telemedicine hub or kiosk ... pulse rate in pediatric to adult patients. The Model ...
(Date:8/28/2014)... According to a new market ... Market (Tags, Readers, Middleware, Printers and Cabinets) - Global ... - 2020" the global radiofrequency identification (RFID) market was ... expected to grow at a CAGR of 13.9% from ... USD 5.3 billion in 2020. Browse the ...
Breaking Medicine Technology:Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5Nonin Medical Announces FDA Clearance of Nonin Model 3231 USB Pulse Oximeter 2Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 2Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 3Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 4Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 5
... , CARSON CITY, Nev. , ... the launch of www.BionicCigs.com , the premiere website for ... this exciting new product that helps smokers wishing to quit and ... electronic cigarette market is estimated to be a $100 Million ...
... , Feb. 2 Advanced Health Media, LLC ... compliance technology and services, announced it has acquired substantially all ... Piscataway, NJ -based provider of marketing services for the pharmaceutical ... will remain at AHM,s Bridgewater, N.J. office. Terms ...
Cached Medicine Technology:Rapid Fire Marketing Enters Electronic Cigarette Market 2Advanced Health Media Acquires Advogent 2Advanced Health Media Acquires Advogent 3
(Date:8/28/2014)... Lake Worth, FL (PRWEB) August 28, 2014 ... promote National Recovery Month throughout September. This month ... of addiction treatment and mental health services. Along ... Millennium Treatment Group is helping to spread the ... Month began in 1989, honoring the work of ...
(Date:8/28/2014)... American adults who are beginning to research ... now have a simpler way to connect with companies ... year, some of the best life insurance rates available ... The promoted plans that included price data revealed to ... policies. The term, guaranteed and modified plans that might ...
(Date:8/28/2014)... 2014 ABC television stars will join ... Show of Strength Telethon airing Sunday, Aug. 31, 9/8c ... raise funds and awareness to help save and improve ... disease. , Viewers tuning into the 2014 telethon to ... and introductions from some of the network’s leading stars, ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 ... announced today a regional partnership designed to advance ... planning for competitive young athletes, scholastic athletes and ... partnership’s Strong Body & Mind Initiative will offer ... both the physical and mental dynamics involved in ...
(Date:8/28/2014)... 28, 2014 Gurnick Academy of Medical ... program is re-accredited for the 5 years of the ... Technologists (ARMRIT). , “We are very proud to ... our program to make sure we provide the best ... interest in MRI field nowadays and I look forward ...
Breaking Medicine News(10 mins):Health News:Millennium Treatment Group Celebrates National Recovery Month 2Health News:Best Life Insurance Rates for 2014 Now Promoted at Insurer Website 2Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 2Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 3Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 4Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 2Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 3Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 4Health News:Gurnick Academy’s MRI Program Is Re-Accredited by ARMRIT for the 5 Years 2
... Medicine have just developed an advanced imaging technique to ... white blood cells. Microdomains are restricted areas on the ... molecules accumulate during cell activation. Using digital multi-channel videomicroscopy, ... and their forming microdomains in the vascular system in ...
... national guidelines recommend that, if managed, may have prevented ... in the issue of Neurology, the scientific journal of ... study of 1,040 people hospitalized for stroke or transient ... higher than recommended by national guidelines. TIA happens when ...
... But they are still just as sensitive as anyone else. Ignoring ... so//. ,Members of the "stronger sex" often expect a ... Many only consult a doctor when it's too late and could ... ,German men have a life expectancy of around 76 years, compared ...
... who smoke are increasingly at the risk of becoming ... turn into active TB disease//, according to an analysis ... Medicine. ,About one-third of the world’s population is ... the organism is usually rendered inactive by the immune ...
... molecular mechanisms behind most of the body’s sensing capabilities. Vision, ... pigment molecule that is extremely sensitive to light. It is ... decoded by the brain into visual information. But how the ... temperature has remained a mystery. ,“For a ...
... drug Vandetanib, marketed by London company AstraZeneca PLC// has begun. ... of lung cancer in whom the first-line treatment has failed. ... , The patients who have a recorded a case ... be given the once-daily drug Vandetanib in addition to pemetrexed, ...
Cached Medicine News:Health News:New Imaging Technique Tracks Traffic Patterns of White Blood Cells 2Health News:Cholesterol in Stroke Patients Exceeds National Guidelines 2Health News:Men Not as Tough as They Seem 2Health News:Susceptibility to TB is High Among the Smokers 2Health News:Researchers Discover Key to Body’s Ability to Detect Subtle Temperature Change 2Health News:Researchers Discover Key to Body’s Ability to Detect Subtle Temperature Change 3
Stainless steel. Lamp is in fiberoptic handle. Green color coding. The blade includes a port that permits delivery of oxygen or other gas mixtures during intubation....
... of the vocal cords in even the most ... like a standard laryngoscope, Viewmax® does not require ... its ability to allow intubation whether you are ... airway. It has a patented lens system that ...
... Stainless steel. Lamp supplied with ... operate on any standard/conventional handle allowing ... illumination without the potential confusion from ... blades offer an easy and cost ...
... The FR-120F, Fujinon's new fiberoptic Naso-Pharyngo-Laryngoscope provides ... patient comfort. The latest in Fujinon ... increased light guide, and a wide 90 ... impressive 3.3mm distal tip diameter. In ...
Medicine Products: